Flaig, T. W., Rosenberg, J. E., Hoimes, C. J., O’Donnell, P. H., Mar, N., Gourdin, T. S., … Petrylak, D. P. (2023). Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Flaig, Thomas W., Jonathan E. Rosenberg, Christopher J. Hoimes, Peter H. O’Donnell, Nataliya Mar, Theodore Stewart Gourdin, Stephanie Henry, et al. “Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Flaig TW, Rosenberg JE, Hoimes CJ, O’Donnell PH, Mar N, Gourdin TS, et al. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Flaig, Thomas W., et al. “Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Flaig TW, Rosenberg JE, Hoimes CJ, O’Donnell PH, Mar N, Gourdin TS, Henry S, Bilen MA, George S, Barata PC, Srinivas S, Rao SK, Assikis VJ, Burgess EF, Ramamurthy C, Haas GP, Lukas JJ, Mildiner-Earley S, Yu Y, Petrylak DP. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. JOURNAL OF CLINICAL ONCOLOGY. 2023.